177lu-psma-i&t
mAbexperimental
Clinical trial activity
2 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 20, 2020 (NCT04443062)
Timeline
Indications
Studied for
Mechanism of action
- Glutamate carboxypeptidase IIImmunity, passive
FOLH1 immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- 177-Lutetium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04886986 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2021 | Cornell University, POINT Biopharma |
| NCT04443062 | Phase 2 | Jul 20, 2020 | Advanced Accelerator Applications, Prostaatkankerstichting, Radboud University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Advanced Accelerator Applications | For profit | 1 | 0 | 1 | 2020 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| POINT Biopharma | For profit | 1 | 0 | 1 | 2021 |
| Prostaatkankerstichting | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Radboud University | Academic/Hospital | 1 | 1 | 1 | 2020 |
5 organizations
Page 1 / 1